A5015037372- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
- Advanced Radiotherapy Techniques
- Hormonal and reproductive studies
- Bladder and Urothelial Cancer Treatments
- Cancer, Lipids, and Metabolism
- Radiopharmaceutical Chemistry and Applications
- Glioma Diagnosis and Treatment
- Head and Neck Cancer Studies
- Radiomics and Machine Learning in Medical Imaging
- Radiation Therapy and Dosimetry
- Urinary and Genital Oncology Studies
- Management of metastatic bone disease
- Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Diagnosis and Treatment
- PARP inhibition in cancer therapy
- Advances in Oncology and Radiotherapy
- Urological Disorders and Treatments
- Hepatocellular Carcinoma Treatment and Prognosis
- Fibroblast Growth Factor Research
- Bone health and treatments
- Estrogen and related hormone effects
- Medical Imaging Techniques and Applications
Vall d'Hebron Hospital Universitari
2016-2025
Central University of Ecuador
2025
Vall d'Hebron Institute of Oncology
2018-2024
Hebron University
2022-2024
Hospital Valle del Nalón
2024
Universitat Autònoma de Barcelona
2002-2020
Vall d'Hebron Institut de Recerca
2014
Prostate Cancer UK
2010
Institut Català d'Oncologia
2010
LBA5000 Background: PEACE-1 demonstrated that combining ADT and docetaxel with abiraterone acetate plus prednisone (AAP) improves both overall survival (OS) radiographic progression-free-survival (rPFS) in men de novo mCSPC. The present analysis examines the second pre-planned primary endpoint of low-volume population: impact prostate irradiation (RT) receiving intensified systemic treatment. Methods: is an academic, multicentre, international, 2x2 design, phase 3 trial. co-primary endpoints...
Glioblastoma (GB) is the most common brain malignancy and accounts for over 50% of all high-grade gliomas. Radiotherapy (RT) with concomitant adjuvant temozolomide (TMZ) chemotherapy current standard care patients newly diagnosed GB up to age 70. Recently, a new has been adopted elderly (≥ 65 years) based on short course RT TMZ. Several clinically relevant molecular markers that assist in diagnosis prognosis have recently identified. The treatment recurrent not well defined, decision-making...
The surrogacy of biochemical recurrence (BCR) for overall survival (OS) in localized prostate cancer remains controversial. Herein, we evaluate the BCR using different analytic methods.Individual patient data from 11 trials evaluating radiotherapy dose escalation, androgen deprivation therapy (ADT) use, and ADT prolongation were obtained. Surrogate candidacy was assessed Prentice criteria (including landmark analyses) two-stage meta-analytic approach (estimating Kendall's tau R2)....
5000 Background: Historically, androgen deprivation therapy (ADT) was the standard of care (SOC) for men with mCSPC. Since 2015, combining ADT either docetaxel, novel hormonal therapies, or radiotherapy to primary tumor (RXT) (for those low burden metastases) shown improve overall survival (OS) and thus has become new SOC. It is unknown whether these treatments on top further increments outcomes. Methods: Men de novo mCSPC were randomized SOC, SOC + abiraterone acetate-prednisone...
<h3>Importance</h3> Radiotherapy combined with androgen deprivation therapy (ADT) is a standard of care for high-risk prostate cancer. However, the interplay between radiotherapy dose and required minimum duration ADT uncertain. <h3>Objective</h3> To determine specific threshold that provides distant metastasis-free survival (DMFS) benefit in patients cancer receiving external beam (EBRT) or EBRT brachytherapy boost (EBRT+BT). <h3>Design, Settings, Participants</h3> This was cohort study 3...
The utilization of Androgen Deprivation Therapy (ADT) in conjunction with Stereotactic Body Radiotherapy (SBRT) and Brachytherapy (BT) boost prostate cancer treatment is a subject ongoing debate evolving clinical practice. While contemporary trends lean towards underutilizing ADT these modalities, existing evidence suggests that its omission may lead to potentially inferior oncologic outcomes. Recommendations for use should be patient-centric, considering individual risk profiles...
Highlights•RAD51-IF is feasible in FFPE clinical biopsies from patients with advanced prostate cancer•Low RAD51 scores associate alterations BRCA1/2•Low improved outcomes PARPi or platinum chemotherapy•RAD51-IF captures HRR restoration of function upon drug resistanceSummaryMetastatic cancer (mPC) enriched for homologous recombination repair (HRR) gene alterations, which have prognostic and predictive value. Routine implementation next-generation sequencing (NGS) still limited. We...
In oncology, patients with advanced cancer are often subjected to treatments limited therapeutic value. This phenomenon is amplified through drug litigation, where interpretations of the right life and health can lead decisions that fail adequately consider evidence real benefits. descriptive study analyzed discrepancies between key arguments in judicial rulings favored access oncological drugs outcomes related clinical trials. We reviewed 5 issued Ecuador 2012 2018 represented claims from...
15 Background: Docetaxel improves survival in patients (pts) with metastatic hormonosensitive prostate cancer (PC) and castration-resistant cancer. The objective of this phase IIb trial was to assess the activity low dose docetaxel concurrent radiotherapy plus standard hormonal treatment pts high risk localized CaP. Methods: High-risk CaP defined by ≥ 1 following criteria: T3-T4, Gleason score (GS) 8, PSA > 20 ng/mL, pN+. Pts were randomly assigned either arm A (LH-RH analogs every 3...